home · filing · 0001493152-23-011261
8-K
filed April 6, 2023, 7:59 PM ET
ticker GCTK
CIK 0001506983
other material
confidence high
sentiment negative
materiality 0.15
GlucoTrack shareholder meeting shows low support for directors and say-on-pay
Glucotrack, Inc.
Directors received only 18.58%-19.00% votes for; broker non-votes of 488,583.
Ratification of auditor passed with 55.55% votes for (8,612,584 votes for).
Nonbinding say-on-pay proposal received 18.34% votes for (2,844,095 votes for).
Annual meeting held March 31, 2023; results reflect significant withheld votes.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Glucotrack, Inc. shareholders approved Election of Directors at the 2023-03-31 meeting.
Proposal director election
Outcome passed
Meeting 2023-03-31
Exact text from the filing
DIR # VOTES FOR VOTES WITHHELD BROKER NON-VOTE % VOTES FOR Dr. Robert Fischell 2,881,036.00 5,250,502.00 488,583.00 18.58 Luis Malave 2,880,918.00 5,250,620.00 488,583.00 18.58 Andrew Sycoff 2,945,847.00 5,185,691.00 488,583.00 19.00 Shimon Rapps 2,882,073.00 5,249,465.00 488,583.00 18.59 Allen Danzig 2,880,916.00 5,250,622.00 488,583.00 18.58
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Glucotrack, Inc. shareholders rejected Nonbinding Say on Pay at the 2023-03-31 meeting.
Proposal say on pay
Outcome failed
Meeting 2023-03-31
Exact text from the filing
Nonbinding Say on Pay 2,844,095.00 5,205,181.00 82,262.00 488,583.00 18.34
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Glucotrack, Inc. shareholders approved Ratify Auditor at the 2023-03-31 meeting.
Proposal auditor ratification
Outcome passed
Meeting 2023-03-31
Exact text from the filing
Ratify Auditor 8,612,584.00 7,481.00 56.00 0.00 55.55
View on SEC.gov
Source: SEC EDGAR
accession 0001493152-23-011261
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.